poster

Safety And Tolerability of Multiple-Dose Aripiprazole 2-Month Ready-to-Use 960 mg Versus Aripiprazole Once-Monthly 400 mg in Adults With Schizophrenia or Bipolar I Disorder

Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, inten...

01/19/2023

IMPACT-TD Registry: Real-World Assessment of the Impact and Progression of Tardive Dyskinesia

Abstract: Background: The long-term impact, burden, and treatment patterns of tardive dyskinesia (TD) are not well understood. Patient- and clinician-reported outcomes are important in de...

01/19/2023

Impact of Tardive Dyskinesia on Physical Aspects of Patient Lives: A Survey of Patients and Caregivers in the United States

Abstract: Background: Tardive dyskinesia (TD) substantially impacts patients’ ability to function in their daily lives. This study assessed physical functioning of patients with TD from t...

01/19/2023

Digital Health Technologies in Mental Health Care: Changing Perspectives of Health Care Professionals from 2019 to 2021

Abstract: Background Demand for digital mental health tools has risen since the start of the COVID-19 pandemic1; however, their evolving use in mental health care is not well understood. ...

01/19/2023

Emraclidine as a Novel Positive Allosteric Modulator Targeting M4 Muscarinic Receptors: Results From a Phase 1b Trial in Patients With Schizophrenia

Abstract: Background: Emraclidine is a novel, highly selective, M4 muscarinic receptor positive allosteric modulator in development for treating schizophrenia. Here, we describe safety, t...

01/19/2023

COMP360 Psilocybin Therapy in Treatment-Resistant Depression: Results of a Large Randomized Controlled Phase IIb Monotherapy Study and an Exploratory Uncontrolled Adjunctive Therapy Study

Abstract: COMP360 is a synthetic purified form of psilocybin in development for treatment of adults with treatment-resistant depression (TRD). COMP360 psilocybin therapy combines oral COM...

01/19/2023

Evaluation of the Innovative Drug Delivery Technology Utilized in TV-46000, a Subcutaneous Long-acting Injectable Risperidone Formulation

Abstract: Background TV-46000 is a risperidone extended-release suspension for subcutaneous administration in development for treatment of patients with schizophrenia. TV-46000 is based o...

01/19/2023

Caregiver Insights on Naloxone to Reverse Opioid/Fentanyl Overdosing

Abstract: Introduction: The aim of this research was to gain caregiver insights on their previous use and current attitudes of naloxone to reverse opioid overdoses, including different ro...

01/19/2023

Visual Hallucinations and Altered Mental Status Exacerbation Associated with Acute Levodopa Withdrawal

Abstract: A 70s-aged female Parkinson’s Disease patient was admitted for encephalopathy, affective changes, and hallucinations. She was anxious, but intermittently alert and oriented. She...

01/19/2023

Pharmacokinetic Profile of Multiple-Dose Aripiprazole 2-Month Ready-to-Use 960 mg Versus Aripiprazole Once-Monthly 400 mg in Adults With Schizophrenia or Bipolar I Disorder

Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, inten...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products